Search | IOVS | ARVO Journals

View

Showing 1 – 7 of 7

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2015

Improvements in Signs and Symptoms of Dry Eye with MIM-D3 1% Ophthalmic Solution Compared to Placebo in Different Patient Populations

Karen Meerovitch; Kim Brazzell; George W Ousler; Garth Cumberlidge

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4460. doi:

ARVO Annual Meeting Abstract June 2013

Relating Improvements in Signs and Symptoms to Duration of Dry Eye Disease (DED) after Treatment with MIM-D3 Ophthalmic Solutions

Karen Meerovitch; Teresa Lama; Debra Schaumberg

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4340. doi:

ARVO Annual Meeting Abstract June 2013

High CAE Responders Show Greater Improvement in Signs and Symptoms of Dry Eye after Treatment with MIM-D3

George Ousler; Karen Meerovitch

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4343. doi:

ARVO Annual Meeting Abstract March 2012

Safety and Efficacy of Topical Ophthalmic MIM-D3, a Novel TrkA Receptor Agonist, in a Phase 2 Clinical Trial for the Treatment of Dry Eye

Karen Meerovitch; Gail Torkildsen; John Lonsdale; Heidi Goldfarb; Teresa Lama; Garth Cumberlidge; George W. Ousler, III

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):578. doi:

ARVO Annual Meeting Abstract April 2009

Neurotrophins Peptidomimetics Protect Retinal Pigment Epithelial (RPE) Cells Against Oxidative Stress-induced Apoptosis

P. K. Mukherjee; K. Meerovitch; T. Lama; H. U. Saragovi; N. G. Bazan

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):2163. doi:

ARVO Annual Meeting Abstract April 2009

An NGF Mimetic, MIM-D3, Demonstrates Therapeutic Efficacy in a Rat Model of Scopoloamine-Induced Dry Eye

R. Li; K. Meerovitch; T. Lama; P. Jain; H. U. Saragovi; G. Cumberlidge

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):3661. doi:

ARVO Annual Meeting Abstract April 2009

An NGF Mimetic, MIM-D3, is a Mucin Secretagogue

K. Meerovitch; P. Jain; T. Lama

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4261. doi:

Advertisement